相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2010
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- The University of Birmingham will receive £10M from the UK Government's Life Sciences Innovative Manufacturing Fund to develop three GMP-standard cleanrooms for advanced therapy manufacturing. - The facility will enable production of cell and gene therapies, mRNA vaccines, and medicines for clinical trials, addressing the West Midlands' lack of dedicated GMP manufacturing despite hosting over 50% of UK's advanced therapy trials. - The investment supports Birmingham's leadership in personalized medicine, including Europe's first trial of personalized mRNA vaccines for pancreatic cancer. - The new biomanufacturing capability will strengthen pandemic preparedness and reduce reliance on overseas manufacturing for UK-funded companies.
- Aleta Biotherapeutics and Cancer Research UK reported promising Phase I/II data for ALETA-001, a first-in-class CAR T-cell engager, showing highly tolerable safety profile across all tested doses. - The trial demonstrated robust CAR T-cell expansion in four of six patients receiving lowest doses and encouraging clinical responses in patients with relapsed or refractory B-cell malignancies. - ALETA-001 works by binding CD19 to CD20 antigen, enabling dual-antigen targeting and improving effectiveness of CD19-directed CAR T-cell therapies through increased antigen density. - The ongoing multi-center UK trial includes dose escalation from 0.4 mg/kg to 6.0 mg/kg with two distinct cohorts examining early and late dosing regimens post-CAR T therapy.
- New findings from the PROCLIPI study, spanning 19 countries and over 2,000 patients, demonstrate a meaningful overall survival advantage for advanced cutaneous T-cell lymphoma patients treated with mogamulizumab. - Among 371 patients with advanced mycosis fungoides and Sézary syndrome, those receiving mogamulizumab showed median overall survival of 64 months compared to 54 months for those not receiving the therapy. - For Sézary syndrome patients specifically, median survival reached approximately 6.5 years with mogamulizumab treatment versus 3 years for those on other systemic treatments. - The study represents one of the largest international registries in cutaneous T-cell lymphoma research, highlighting the power of global collaboration in rare disease evidence generation.
- The European Respiratory Society Congress 2024 highlighted key ethical principles for AI integration in healthcare, including patient autonomy, beneficence, and the need for explainable AI systems. - Studies revealed significant accuracy concerns in AI healthcare applications, with one system missing 67% of sepsis cases and showing bias in diagnosing conditions across different demographic groups. - AI's environmental impact raises sustainability concerns, with healthcare AI technologies projected to consume as much power as Japan by 2026, prompting discussions on balancing innovation with ecological responsibility.
